An interventional study of Brain Health Program in Dementia and Alzheimer Disease, sponsored by Posit Science Corporation. Completed at 1 site in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-07-27.
Sponsored by Posit Science Corporation · Not applicable, Interventional, and Treatment
Among 1,937 studies in Alzheimer Disease with a site in United States — 343 open to participants now, 444 under way, 39 of them phase 3. Alzheimer Disease · United States.
Among the 1,937 studies in Alzheimer Disease with a site in United States, this one is the 726th largest by enrollment of the 1,606 interventional ones that give a count, is one of 115 that started in 2023, is one of 607 with no phase, and was the 1,502nd registered.
3,965 studies on the registry are indexed under Alzheimer Disease; 926 are open to participants now.
Browse Alzheimer Disease studies →343 of the 1,937 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:
National Institute on Aging (NIA) · Sites in United States
Prevention Research Consortium Corp. · Sites in United States
National Institute on Aging (NIA) · Sites in United States
Hoffmann-La Roche · Sites in United States, Australia, France
University of Wisconsin, Madison · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 641 Alzheimer Disease studies recruiting now, 283 (44%) set no upper age limit and 54 (8%) stop at 75 or younger; 34 take children under 18; 283 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,937 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 371 · Phase 2 468 · Phase 3 229 · Phase 4 60
First in 1981; this study’s year is marked. 115 started in 2023.
This study's enrollment of 86 is above the median of 70 across 3,019 interventional studies indexed under Alzheimer Disease.
Median enrollment 73 across the 1,606 interventional studies, 160 across the 309 observational. Of the 1,376 that completed or were terminated, 590 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
730 of 1,937 have an industry lead sponsor. The 10 most frequent:
Posit Science Corporation is the lead sponsor of 36 studies on the registry; 1 is open to participants now.
Posit Science Corporation has 2 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
164 of the studies in Alzheimer Disease with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT06126224Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | 2026-12-09 |
| NCT03860857Phase 3University of California, IrvineBiomarker Exploration in Aging, Cognition and Neurodegeneration | 2026-12-22 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
Among the 1,937 studies in Alzheimer Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a validation study to evaluate the acceptability, feasibility and preliminary efficacy of the Brain Health Program, a multimodal curriculum covering dementia risk factors and evidence-based change interventions. The goal of this study is to evaluate the Brain Health Program in individuals with identified risk factors for the onset of dementia and to prepare for a large-scale efficacy trial in this population.
This study will employ an evidence-based Brain Health Program curriculum, which involves a twelve-week, group-administered, personalized program designed to improve brain health in individuals with identified risk factors for the onset of dementia. This is a single-arm open-label feasibility study, enrolling older adults with Alzheimer's disease risk factors in a public health, community-deployed, group-based and individualized multimodal Brain Health Program (targeting, among other domains, diet, exercise and cognitive exercise), with a set of baseline assessments intended to characterize the population, and outcome measure to evaluate the usability of the program, as well as preliminary efficacy to reduce dementia risk factors.
3,965 studies on the registry are indexed under Alzheimer Disease; 926 are open to participants now.
This study's enrollment of 86 is above the median of 70 across 3,019 interventional studies indexed under Alzheimer Disease.
Browse Alzheimer Disease studies →Posit Science Corporation is the lead sponsor of 36 studies on the registry; 1 is open to participants now.
Compared within Alzheimer Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dementia. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants who meet criteria for one or more ADRD dementia risk factors
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A multimodal educational and interactive diet, exercise and computerized cognitive exercise public health program.
Other: Brain Health Program
The Brain Health Program employs 1-hour/week group-based training and education regarding modifiable Alzheimer's disease dementia risk factors delivered over a 12-week period. Participants will be assigned into a group of up to 20 participants, and participants will engage the Brain Health Program collaboratively, as administered by the program content leader (instructor), while also being monitored and supported by the tech leader (in accordance with the Diabetes Prevention Program model).
Net Promoter Score
NPS (Net Promoter Score) is a whole number on a scale of -100 to +100, calculated by subtracting the percentage of Detractors from the percentage of Promoters. Promoters (score 9-10) are likely to exhibit value-creating behaviors, such as referring other potential program participants. Detractors (score 0-6) are less likely to do so. Passives (score 7-8) fall in between. Passives count toward the total number of respondents, which decreases the percentage of Promoters and Detractors and pushes the score toward 0. Higher score is better.
Time frame: At 12 weeks
Percentage of Participants Who Complete at 80% of Intended Program Sessions.
Time frame: At 12 weeks
Program Comprehension
One of the post-program survey questions asked participants whether the program was easy to comprehend. This was measured on a 7-point Likert scale, ranging from 1 ("totally disagree") to 7 ("totally agree"). Higher score means a better outcome.
Time frame: At 12 weeks
Relevancy of Program
One of the post-program survey questions asked participants whether the program was relevant. This was measured on a 7-point Likert scale, ranging from 1 ("totally disagree") to 7 ("totally agree"). Higher score means a better outcome.
Time frame: At 12 weeks
Program Awareness
One of the post-program survey questions asked participants whether the program effectively raised awareness about brain health and how to manage it. This was measured on a 7-point Likert scale, ranging from 1 ("totally disagree") to 7 ("totally agree"). Higher score means a better outcome.
Time frame: At 12 weeks
Program Work Assignments
One of the post-program survey questions asked participants whether the work assigned in the program was reasonable. This was measured on a 7-point Likert scale, ranging from 1 ("totally disagree") to 7 ("totally agree"). Higher score means a better outcome.
Time frame: At 12 weeks
Positive Lifestyle Change Post-program
One of the post-program survey questions asked participants whether the program helped to make a positive lifestyle change. This was measured on a 7-point Likert scale, ranging from 1 ("totally disagree") to 7 ("totally agree"). Higher score means a better outcome.
Time frame: At 12 weeks
Program Satisfaction
One of the post-program survey questions asked participants whether the program was satisfying. This was measured on a 7-point Likert scale, ranging from 1 ("totally disagree") to 7 ("totally agree"). Higher score means a better outcome.
Time frame: At 12 weeks
| Milestone | Brain Health Program |
|---|---|
| Started | 71 |
| Completed | 66 |
| Not completed | 5 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Withdrawn by investigator | 2 |
NPS (Net Promoter Score) is a whole number on a scale of -100 to +100, calculated by subtracting the percentage of Detractors from the percentage of Promoters. Promoters (score 9-10) are likely to exhibit value-creating behaviors, such as referring other potential program participants. Detractors (score 0-6) are less likely to do so. Passives (score 7-8) fall in between. Passives count toward the total number of respondents, which decreases the percentage of Promoters and Detractors and pushes the score toward 0. Higher score is better.
| score on a scale | Brain Health Program |
|---|---|
| Net Promoter Score | 65 (51 to 79) |
| Participants | Brain Health Program |
|---|---|
| Percentage of Participants Who Complete at 80% of Intended Program Sessions. | 66 |
One of the post-program survey questions asked participants whether the program was easy to comprehend. This was measured on a 7-point Likert scale, ranging from 1 ("totally disagree") to 7 ("totally agree"). Higher score means a better outcome.
| score on a scale | Brain Health Program |
|---|---|
| Program Comprehension | 6.5 ± 0.64 |
One of the post-program survey questions asked participants whether the program was relevant. This was measured on a 7-point Likert scale, ranging from 1 ("totally disagree") to 7 ("totally agree"). Higher score means a better outcome.
| score on a scale | Brain Health Program |
|---|---|
| Relevancy of Program | 6.2 ± 0.77 |
One of the post-program survey questions asked participants whether the program effectively raised awareness about brain health and how to manage it. This was measured on a 7-point Likert scale, ranging from 1 ("totally disagree") to 7 ("totally agree"). Higher score means a better outcome.
| score on a scale | Brain Health Program |
|---|---|
| Program Awareness | 7.0 ± 0.71 |
One of the post-program survey questions asked participants whether the work assigned in the program was reasonable. This was measured on a 7-point Likert scale, ranging from 1 ("totally disagree") to 7 ("totally agree"). Higher score means a better outcome.
| score on a scale | Brain Health Program |
|---|---|
| Program Work Assignments | 6.8 ± 0.77 |
One of the post-program survey questions asked participants whether the program helped to make a positive lifestyle change. This was measured on a 7-point Likert scale, ranging from 1 ("totally disagree") to 7 ("totally agree"). Higher score means a better outcome.
| score on a scale | Brain Health Program |
|---|---|
| Positive Lifestyle Change Post-program | 6.8 ± 0.76 |
One of the post-program survey questions asked participants whether the program was satisfying. This was measured on a 7-point Likert scale, ranging from 1 ("totally disagree") to 7 ("totally agree"). Higher score means a better outcome.
| score on a scale | Brain Health Program |
|---|---|
| Program Satisfaction | 6.1 ± 0.89 |
Collected over Adverse event data are collected throughout the study duration. Study participation is 12 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brain Health Program | 0/71 (0%) | 0/71 (0%) | 2/71 (2.8%) |
| Event | Brain Health Program |
|---|---|
| FallMusculoskeletal and connective tissue disorders | 1/71 |
| Eye StrainEye disorders | 1/71 |
| Age, Continuous(years) | Brain Health Program |
|---|---|
| Mean | 74.5 ± 5.8 |
| Sex: Female, Male(Participants) | Brain Health Program |
|---|---|
| Female | 59 |
| Male | 12 |
| Ethnicity (NIH/OMB)(Participants) | Brain Health Program |
|---|---|
| Hispanic or Latino | 17 |
| Not Hispanic or Latino | 53 |
| Unknown or Not Reported | 1 |
| Race (NIH/OMB)(Participants) | Brain Health Program |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 17 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 41 |
| More than one race | 2 |
| Unknown or Not Reported | 11 |
| Years of Education(years) | Brain Health Program |
|---|---|
| Mean | 16 ± 3.5 |
| Cognitive Abilities Screening Instrument-Short (CASI-Short)(units on a scale) | Brain Health Program |
|---|---|
| Mean | 31.2 ± 2.1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2023 to primary completion in Oct 2024, 17 months.
Results were first posted in Jul 2026, 1 year 9 months after primary completion.
Of 77 industry-sponsored interventional studies with no phase under Alzheimer Disease, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 40. This study's 17 months is below that.
Counting every sponsor, half of 959 studies reached it within 29 months; a quarter within 15 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.